Abstract
Overexpression of the c-erbB-2 proto-oncogene in mammary carcinoma is frequently associated with amplification of the c-erbB-2 gene, but it also occurs from single-copy gene. Studies in mammary-derived cell lines have shown that, whether or not the gene is amplified, there is a 6- to 8-fold increase in the accumulation of c-erbB-2 mRNA per gene copy in overexpressing cells. We have recently shown that this phenomenon is due to increased activity of the c-erbB-2 promoter mediated by the binding of a novel transcription factor, OB2-1, which is present at higher levels in overexpressing cells than in low expressors. OB2-1 activity therefore represents a novel therapeutic target for the down-regulation of c-erbB-2 levels in human cells. As a prototype for this strategy, we show here that the drug sodium aurothiomalate is able to inhibit the DNA-binding activity of OB2-1 in vitro and also to interfere with c-erbB-2 promoter activity in cell-based transfection assays. In addition, endogenous c-erbB-2 immunoreactivity was reduced in cells treated with aurothiomalate as compared with the levels observed in control cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hollywood, D., Hurst, H. Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma. Br J Cancer 71, 753–757 (1995). https://doi.org/10.1038/bjc.1995.146
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.146
This article is cited by
-
tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)
BMC Cancer (2008)
-
Giacomo Castelvetro’s salads. Anti-HER2 oncogene nutraceuticals since the 17th century?
Clinical and Translational Oncology (2008)
-
HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
British Journal of Cancer (2003)
-
Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment
Breast Cancer Research (2001)
-
Ets regulation of the erbB2 promoter
Oncogene (2000)